Senior Procurement Contract Specialist at Legend Biotech

Franklin Township, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

A bachelor’s degree or higher in fields such as Business Administration, Law, or Finance or a related discipline
A minimum of 5 years’ relevant experience in Sourcing/Procurement, Supply Chain or similar within the FMCG or pharmaceutical industries
A strong working knowledge of contract law, legal terminology, and Procurement best practices required
Proficiency in MS Office required
Experience within an ERP (ie: SAP) preferred
Experience with Contract Lifecycle Management platform preferred

Responsibilities

Lead or support negotiations across various Procurement categories, including pricing, payment structure, and other business-related terms and conditions with external parties (vendors, clients, partners) to achieve favorable outcomes and secure mutually beneficial agreements
Ensure assigned contracts adhere to internal company policies. Identify potential risks and develop mitigation strategies. Ensure contract terms are reflected in Legend’s ERP system
Oversee contract execution and monitor performance to ensure all parties meet their respective contractual obligations and deadlines. This may include tracking deliverables, expenditures, and renewals/expirations
For assigned contracts, serve as the primary liaison between the Procurement organization, external parties, and internal departments to address contract-related inquiries and issues
Partner with Legend’s Legal Department to maintain an organized, centralized system or database for all contract documentation, records, and reports
Manage contract change orders, amendments, and extensions, and work to resolve any disputes that may arise during the contract period
Authority to make decisions related to contractual outcomes, in alignment with Procurement leadership, Legend’s Legal Department, and the relevant business function. Senior leadership approval is required for higher-value contracts, including those involving significant budget allocations, strategic shifts, or major collaborations with substantial financial or long-term implications

Skills

Procurement

Contract Negotiation

Contract Management

Compliance

Risk Management

ERP Systems

Vendor Management

Pricing Negotiation

Payment Structures

Business Terms

Legend Biotech

Develops and commercializes cell therapies

About Legend Biotech

Legend Biotech develops and commercializes cell therapies aimed at treating serious diseases, particularly cancers like hematological malignancies and solid tumors. Their approach is technology agnostic, allowing them to explore various methods to find effective treatments. The company operates in the personalized medicine sector, focusing on discovering, developing, and bringing new therapies to market. They generate revenue through licensing and selling their therapies, including CAR-T therapies, which involve modifying a patient's cells to combat cancer. Legend Biotech emphasizes transparency with investors, regularly updating them on financial results and business developments.

Franklin Township, New JerseyHeadquarters

2014Year Founded

$146.4MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

1,001-5,000Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Sick Leave

Paid Holidays

Remote Work Options

Risks

Increased competition from Amgen's Imdelltra may impact CAR-T therapy focus.

Collaboration with Multiply Labs may face technological challenges, delaying production timelines.

Financial strain from new R&D facility could affect operational focus if advancements lag.

Differentiation

Legend Biotech focuses on novel cell therapies for oncology, including CAR-T and NK cells.

The company is technology agnostic, exploring multiple platforms for effective cancer treatments.

Legend Biotech's CARVYKTI® is the first BCMA-targeted CAR-T therapy approved for second-line use.

Upsides

Recent FDA and European approvals for CARVYKTI® expand its market reach in multiple myeloma.

New R&D facility in Philadelphia boosts innovation in next-generation cell therapies.

Alan Bash's appointment could accelerate CARVYKTI®'s growth and market penetration.

Land your dream remote job 3x faster with AI

Try Jobo Free